Details for Patent: 8,642,077

Title:	Stable pharmaceutical composition and methods of using same
Abstract:	The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
Inventor(s):	Manku; Mehar (Birmingham, GB), Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT)
Assignee:	Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Filing Date:	Feb 15, 2013
Application Number:	13/768,906
Claims:	1. A method of reducing triglycerides in a subject with mixed dyslipidemia on statin therapy comprising, administering to the subject a pharmaceutical composition comprising about 2500 mg to 5000 mg per day of ethyl eicosapentaenoate and not more than about 5%, by weight of all fatty acids, docosahexaenoic acid or its esters to effect a reduction in fasting triglyceride levels in the subject. 2. The method of claim 1 wherein upon 12 weeks of said administration the subject exhibits a reduction in LDL-C of at least 5% compared to placebo control. 3. The method of claim 1 wherein the subject exhibits a reduction in fasting triglycerides of at least 15% compared to placebo control. 4. The method of claim 1 wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 20% compared to placebo control. 5. The method of claim 1 wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 25% compared to placebo control. 6. The method of claim 1 wherein the subject exhibits a reduction in fasting VLDL-C compared to placebo control. 7. The method of claim 1 wherein the subject exhibits a reduction in fasting VLDL-C of at least 5% compared to placebo control. 8. The method of claim 1 wherein the subject exhibits a reduction in hs-CRP compared to placebo control. 9. The method of claim 1 wherein the subject exhibits a reduction in non-HDL-C compared to placebo control. 10. The method of claim 1 wherein the subject exhibits a reduction in total cholesterol compared to placebo control. 11. The method of claim 1 wherein the subject exhibits a reduction in non-HDL-C, total cholesterol and VLDL-C compared to placebo control. 12. The method of claim 1 wherein the subject exhibits a reduction in oxidized LDL-C compared to placebo control. 13. The method of claim 1 wherein the subject exhibits a reduction in lipoprotein associated phospholipase A2 compared to placebo control. 14. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 500 mg to about 1.5 g of ethyl eicosapentaenoate. 15. The method of claim 14 wherein the dosage units are capsules. 16. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 900 mg to about 1 g of ethyl eicosapentaenoate. 17. The method of claim 16 wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 1 g of ethyl eicosapentaenoate. 18. The method of claim 17 wherein the dosage units are capsules. 19. The method of claim 1 wherein the ethyl eicosapentaenoate comprises at least about 90%, by weight, of all fatty acids.